Core Insights - NANOBIOTIX announced promising initial data from a Phase 1 study evaluating JNJ-1900 (NBTXR3) combined with chemoradiation for patients with locally advanced esophageal adenocarcinoma (EADC) [1][4][6] Company Overview - NANOBIOTIX is a late-stage clinical biotechnology company focused on physics-based therapeutic approaches to improve treatment outcomes for cancer patients [10][12] - The company is headquartered in Paris, France, and is listed on Euronext Paris and NASDAQ [12] Study Details - The study is sponsored by The University of Texas MD Anderson Cancer Center and involves a dose escalation and expansion study of JNJ-1900 (NBTXR3) [1][2] - The study includes two cohorts: cohort 1 with photon chemoradiation and cohort 2 with proton chemoradiation [1] Efficacy and Safety Results - The treatment was well-tolerated in the study population of 13 patients, with an 85% disease control rate (DCR) and a 69% objective response rate (ORR) [4][11] - Six patients underwent surgery post-treatment, with two achieving pathological complete response (pCR) [11] Mechanism of Action - JNJ-1900 (NBTXR3) consists of functionalized hafnium oxide nanoparticles that induce tumor cell death when activated by radiotherapy, potentially enhancing local control and reducing the need for invasive surgeries [7][3] Future Development - The study's results support further investigation of JNJ-1900 (NBTXR3) in combination with proton radiation therapy, which could open new indications for the product [6] - NANOBIOTIX has engaged in collaborations to expand the development of JNJ-1900 (NBTXR3) across various tumor types and therapeutic combinations [9]